Research paper (Apr 2015) :
Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis
Full paper : link
researchers and labs involved :
Ji Miao, Alisha V. Ling, Praveen V. Manthena, Mary E. Gearing, Mark J. Graham, Rosanne M. Crooke, Kevin J. Croce, Ryan M. Esquejo, Clary B. Clish, Morbid Obesity Study Group, David Vicent & Sudha B. Biddinger
This new paper seems to suggest that FMO3 enzyme may play a (negative) role in diabetes and atherosclerosis. This to me would seem to imply that people with FMO3 deficiency may have a protective advantage (?).
The researchers were based at various respected hospitals in USA and Spain.
It seems they investigated 175 metabolites to see which may be associated with insulin resistance and CVD and of these metabolites TMA-oxide was the most noticeable.
It's a bit too technical for me but it seems people with FMO3 deficiency should have a protective advantage but that's not so good if you have 'FMO3 malodor'.
The best news is that this will intensify research into FMO3 enzyme and trimethylamine metabolism in humans as the paper is associating FMO3 and TMA-oxide with diabetes and cardiovascular disease.
Of note is that this research paper did not include the Hazen lab at Cleveland Clinic which first proposed a connection with TMAO and CVD in 2011. So I guess this paper is sort of backing up this connection.
My view on FMO3 and metabolic malodors :
Ji Miao, Alisha V. Ling, Praveen V. Manthena, Mary E. Gearing, Mark J. Graham, Rosanne M. Crooke, Kevin J. Croce, Ryan M. Esquejo, Clary B. Clish, Morbid Obesity Study Group, David Vicent & Sudha B. Biddinger
- 1Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- 2Isis Pharmaceuticals, Carlsbad, California, USA.
- 3Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- 4Metabolic Disease Program and Diabetes and Obesity Center, Sanford-Burnham Medical Research Institute, Orlando, Florida, USA.
- 5Broad Institute, Cambridge, Massachusetts, USA.
- 61] Department of Endocrinology and Nutrition, Hospital Carlos III, Madrid 28029, Spain [2] Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Madrid 28046, Spain.
This new paper seems to suggest that FMO3 enzyme may play a (negative) role in diabetes and atherosclerosis. This to me would seem to imply that people with FMO3 deficiency may have a protective advantage (?).
The researchers were based at various respected hospitals in USA and Spain.
It seems they investigated 175 metabolites to see which may be associated with insulin resistance and CVD and of these metabolites TMA-oxide was the most noticeable.
It's a bit too technical for me but it seems people with FMO3 deficiency should have a protective advantage but that's not so good if you have 'FMO3 malodor'.
The best news is that this will intensify research into FMO3 enzyme and trimethylamine metabolism in humans as the paper is associating FMO3 and TMA-oxide with diabetes and cardiovascular disease.
Of note is that this research paper did not include the Hazen lab at Cleveland Clinic which first proposed a connection with TMAO and CVD in 2011. So I guess this paper is sort of backing up this connection.
My view on FMO3 and metabolic malodors :
Personally I currently suspect FMO3 enzyme may be to blame for most cases of 'metabolic malodors'. This is because FMO3 oxidizes many sulfides and amines in humans. If not FMO3 then one of the other oxidizing enzymes, though my current suspicion is with FMO3.
Get new posts by email
0 comments:
Post a Comment